Report: M&A worth $11 billion in third quarter while Russian market shows promise

6 November 2013

PricewaterhouseCoopers (PwC) has released its quarterly Life Sciences Deals Insights Quarterly for the third quarter of 2013. The report showed that Mergers and Acquisitions (M&A) activity remained strong in the life sciences industry, while changes in Russia’s approach to the pharmaceutical industry could provide opportunities for investors.

Mergers and Acquisitions

Total deal volume across pharmaceuticals, biotech, medical devices, diagnostics and services increased approximately 10% during the third quarter of 2013 in comparison with the second quarter of 2013. Deal value in the pharmaceutical and biotechnology segments decreased sharply relative to levels for the second quarter of 2013 and third quarter of 2012. The number of pharmaceutical deals decreased significantly relative to the second quarter as pharmaceuticals deal value reached $7 billion, while biotech deals were worth $4 billion, compared to $13 billion and $2 billion respectively in the second quarter of 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >